An Observational Study of Afatinib 30 mg Daily in Patients With Advanced Non‐Small‐Cell Lung Cancer Harboring Common EGFR Mutations Treated With Afatinib
Thoracic Cancer · 2026-07 · 17 (13)
DOI: 10.1111/1759-7714.70331 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Thoracic Cancer, online erschienen am 30.06.2026. Verfasst von Kenneth Sooi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology-Oncology, National University Hospital, Singapore, Singapore. Hauptthemen laut MEDLINE: Afatinib, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Mutation. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Boehringer Ingelheim.
Abstract (Originalsprache)
Background
Afatinib is an approved first‐line treatment for advanced non‐small‐cell lung cancer (NSCLC) harboring sensitizing EGFR mutations. At the standard 40 mg dose, 28%–53% of patients in randomized trials required dose reductions due to adverse events (AEs), predominantly cutaneous and gastrointestinal. This study evaluated whether a 30 mg starting dose could improve tolerability without compromising efficacy.
Methods
This multicenter, single‐arm phase 2 study enrolled treatment‐naive patients with advanced EGFR‐mutant NSCLC. Patients received afatinib 30 mg daily until progression or unacceptable toxicity. The primary endpoint was 6‐month progression‐free survival (PFS) rate. Secondary endpoints included median PFS, time‐to‐treatment failure (TTF), objective response rate (ORR), disease control rate (DCR), and safety. Using A'Hern's single‐stage design (one‐sided α = 0.1, 80% power), 62 patients were required to distinguish a target 6‐month of PFS ≥ 75% from ≤ 62%.
Results
The study was terminated early due to slow accrual; 30 patients were enrolled between May 2023 and May 2024. Median follow‐up was 11.3 months (IQR 9.6–15.5). The 6‐month PFS rate was 93.2% (95% CI 75.5–98.3), median PFS of 15.8 months (95% CI 13.4–not reached) and median TTF of 17.0 months. ORR was 80% and DCR 96.7%. Common treatment‐related AEs included diarrhea (83.3%), mucositis (60.0%), paronychia (60.0%), and acneiform rash (46.7%). Grade ≥ 3 AEs occurred in 10.0% of patients, with no Grade 4–5 events. Dose modification was required in 13.3% of patients.
Conclusion
Afatinib 30 mg daily was well tolerated and demonstrated encouraging efficacy, with a 6‐month PFS of 93.2%, suggesting outcomes comparable to standard dosing. Trial Registration: Registration number: NCT04909073; https://clinicaltrials.gov
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Haematology-Oncology, National University Hospital, Singapore, Singapore.
- Department of Medical Oncology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
- Department of Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia.
- Cancer Research and Clinical Trials Center, Vietnam National Cancer Hospital, Hanoi, Vietnam.
- Saw Swee Hock School of Public Health, National University Hospital, Singapore, Singapore.
ORCID-Profile: Pongwut Danchaivijtr
Förderung
- Boehringer Ingelheim
Zitieren
APA
Sooi, K., Danchaivijtr, P., Wong, C. K., Tu, V. D., Sachdeva, M., Tai, B. C., & Soo, R. A. (2026). An Observational Study of Afatinib 30 mg Daily in Patients With Advanced Non‐Small‐Cell Lung Cancer Harboring Common EGFR Mutations Treated With Afatinib. Thoracic Cancer, 17(13). https://doi.org/10.1111/1759-7714.70331
Vancouver
Sooi K, Danchaivijtr P, Wong CK, Tu VD, Sachdeva M, Tai BC, et al. An Observational Study of Afatinib 30 mg Daily in Patients With Advanced Non‐Small‐Cell Lung Cancer Harboring Common EGFR Mutations Treated With Afatinib. Thoracic Cancer. 2026;17(13). doi:10.1111/1759-7714.70331
BibTeX
@article{Sooi2026,
author = {Sooi, Kenneth and Danchaivijtr, Pongwut and Wong, C K and Tu, V D and Sachdeva, Manavi and Tai, B C and Soo, Ross A},
title = {An Observational Study of Afatinib 30 mg Daily in Patients With Advanced Non‐Small‐Cell Lung Cancer Harboring Common EGFR Mutations Treated With Afatinib},
journal = {Thoracic Cancer},
year = {2026},
volume = {17},
number = {13},
doi = {10.1111/1759-7714.70331}
}
EUVIMED